Marksans Pharma Q2 FY27 Revenue Rises 30.5% to ₹940 Crore

Marksans Pharma Ltd reported Q2 FY27 revenue from operations of ₹940.2 crore, a 30.5% year-on-year increase, while EBITDA rose 48.3% to ₹214 crore and margin reached 22.8%. The quarter matters because profitability exceeded the company’s stated annual margin guidance despite cost pressures in active pharmaceutical ingredients and freight.

What did Marksans Pharma report for Q2 FY27?

Marksans Pharma reported its strongest quarterly revenue performance, with revenue from operations reaching ₹940.2 crore in Q2 FY27. Revenue increased 11.8% sequentially from ₹840.8 crore and 30.5% from the corresponding quarter a year earlier. Total income for the quarter was ₹958 crore, up 29.2% year-on-year.

Profitability improved on an annual comparison. Gross profit rose 33.6% to ₹550 crore, and gross margin increased by 135 basis points to 58.5%. EBITDA grew 48.3% to ₹214 crore, taking the EBITDA margin to 22.8%, an expansion of 274 basis points from a year earlier. Net profit rose 44.8% year-on-year to ₹143.5 crore.

Why did profitability improve despite input-cost pressures?

Marksans said revenue growth was accompanied by a stronger profitability profile, with gross profit rising faster than revenue on a year-on-year basis. The 22.8% EBITDA margin was above the company’s stated 20%-21% guidance for the financial year and also above the 21%-22% range referred to in call summaries.

Management nevertheless flagged pressure from rising API and freight costs, and indicated that gross margins could be lower going forward. The supplied call summary also noted that margin, gross margin and profit after tax declined sequentially, although the available material does not provide the corresponding prior-quarter values for these measures. This makes the year-on-year expansion, rather than a single-quarter trend, the clearer basis for assessing the reported improvement.

How is Marksans Pharma using its cash position?

Marksans ended the first half of FY27 with net cash of ₹1,095 crore and reported H1 FY27 net profit of ₹303 crore. During the earnings call, Chairman and Managing Director Mark Saldana said capital allocation would focus on capital expenditure and mergers and acquisitions, including opportunities in Europe and manufacturing facilities in India.

The company is building a front-end presence in Europe, while management also discussed evaluating Indian manufacturing assets. Saldana said potential Indian acquisitions could span different dosage forms, excluding injectables, and would include a solid oral component. He also said the company could face capacity constraints in about two years, which provides context for its evaluation of additional facilities.

What does the Q2 FY27 result mean for investors and operations?

The Q2 FY27 result shows that Marksans expanded sales and operating margin together on a year-on-year basis. Revenue growth of 30.5%, EBITDA growth of 48.3%, and net profit growth of 44.8% indicate that earnings increased faster than sales during the quarter. The company’s net cash balance gives it financial capacity for the capital expenditure and acquisition priorities discussed by management.

At the same time, the call highlighted that part of growth is acquired and that API and freight costs remain relevant to gross-margin performance. For investors, this means the reported quarter combines strong financial delivery with a need to track the contribution of acquired businesses, the pace of European front-end development, and spending on Indian manufacturing capacity. No transaction, value, or completion timeline for acquisitions was disclosed in the provided material.

What has changed in Marksans Pharma’s credit assessment?

India Ratings revised the outlook on Marksans Pharma’s bank loans to Positive from Stable while affirming the company’s IND AA- rating. The change followed a period in which the company reported higher revenue, profitability and a substantial net cash position.

A positive outlook is not a rating upgrade, but it signals that the rating agency has revised its view of the direction of the company’s credit profile. The affirmation of the IND AA- rating remains the current rating position stated in the supplied material. The company’s future capital deployment will remain relevant because management has identified both capex and acquisitions as uses for cash.

Conclusion

Marksans Pharma delivered Q2 FY27 revenue of ₹940.2 crore and net profit of ₹143.5 crore, with EBITDA margin reaching 22.8%. The figures show strong year-on-year operating growth, while the company’s cash balance and Positive credit-rating outlook provide financial context for its planned investment activity.

Investors will watch whether API and freight costs affect gross margins, how the European front-end build-out progresses, and whether Marksans announces manufacturing or acquisition transactions. Management has disclosed its interest in Indian facilities and European acquisitions, but has not disclosed specific targets, transaction values, or completion dates.